Pharma Social Media and Updates
Pharma Social Media and Updates
Pharma Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
One observation here: GLP-1s are priced at maybe 25-50x production cost (not counting R&D). LLM usage is priced at perhaps 1x inference cost (not counting training). In any case, two great innovations that are rapidly catching on.
This is great to see. Biotech and pharma competition with China is going to force us to sharpen and accelerate processes in the US, and cut red tape. And we'll get the benefit of Chinese drugs as well. Win/win.
A potential universal flu shot? Intranasal EV vaccine protected mice from H5N1, H7N9 https://t.co/WroXpi6YP3 https://t.co/umAPlnRjbF
A new adrenal gland organoid accurately models human development and hormone production, offering a platform to study stress responses, disease mechanisms, and potential regenerative therapies for adrenal disorders. biotechnology
Longevity treatments for a 91-year-old. That's the kind of story that captures where Silicon Valley's immortality bet is actually heading. Great piece by @AmyDMarcus, who I had the chance to meet in Boston recently. She brings serious depth to this beat,...
They ported the 5-MeO-DMT pathway from the Sonoran Desert toad into tobacco plants and then used AlphaFold3 to debug the protein structure, leading to a 40x yield increase. Prompt psychedelic design.
Life is a marshmallow test. Incretin modulators help you win while staying happy. I often ask big audiences - "how many of you are on GLP1?" and only a couple hands go up. Sometimes, none. That's when I understood that...
I mis-spoke here. This study showed 5-meo-DMT much more effective than psilocybin. This was specifically on treatment resistant depression. A 15 point MADRS reduction there is ~2x psilocybin and ~3x ketamine. 5-meo-DMT really is the most potent antidepressant known to...
Great conversation with Jamie Bacher about the one challenge synbio must solve: time to market. Jamie argues that scaling biotech requires more than great strains—process dev, downstream, analytics, and new financing models all matter. Excited to have him at #SynBioBeta2026. Read the...
An intranasal vaccine using extracellular vesicles displaying inverted influenza hemagglutinins induced broad, cross-protective immunity in mice, offering a promising strategy for universal flu prevention at the mucosal level. vaccines
NIH would get $5 billion cut under Trump’s 2027 budget, but Congress unlikely to go along https://t.co/PPQbrSBwi0 via @statnews
Trump once again going for draconian cuts to NIH, though not as catastrophic as he sought for the last round (and didn't get). Meanwhile, he wants $1.5T for war. I doubt he'll be any more successful with NIH cuts than...
3April: Which are GEN's first-ever Top 10 Organoid Companies (5 publicly traded, 5 privately held)? And what's driving growth for these and other organoid companies? Check out my latest A-List for @GENbio: https://t.co/6D589lVk9s
Are you pro-bodyoid or anti-bodyoid? For the purpose of this poll, a bodyoid is: a newborn clone of you lacking a cortex, a.k.a. a brainless clone, gestated by a paid surrogate. It's organs are a perfect match (isogenic) to you...
Approved drugs can have a "black box" (aka boxed) warning, the highest safety-related warning that FDA can put on an approved drug Usually applied to multiple drugs in the same class it can hamper revenue potential if alternatives exist Investors should be...
